<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transcatheter pulmonary valve implantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transcatheter pulmonary valve implantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transcatheter pulmonary valve implantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andreas Eicken, MD, PhD, FESC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanimir Georgiev, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H354444672"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transcatheter pulmonary valve implantation (TPVI) is an alternative to surgery for selected patients with right ventricular outflow tract (RVOT) dysfunction [<a href="#rid1">1-3</a>]. TPVI devices were initially developed to treat dysfunctional (stenotic or regurgitant) RV to pulmonary artery conduits. Indications were later expanded to dilated RVOTs following patch placement as valves were introduced for this application. TPVI is intended to reduce the total number of open-heart surgeries required over a patient's lifetime.</p><p class="headingAnchor" id="H378215528"><span class="h1">CLINICAL SETTING</span></p><p class="headingAnchor" id="H3611760353"><span class="h2">Uses</span><span class="headingEndMark"> — </span>TPVI is a treatment for selected patients with RV outflow tract (RVOT) dysfunction involving a bioprosthetic or native pulmonary valve; the valve may be located in an RV to pulmonary artery conduit or in a native RVOT [<a href="#rid2">2-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary regurgitation</strong> with associated criteria<strong> </strong>and mild or no nonvalvular RVOT obstruction, as discussed separately  (<a class="graphic graphic_table graphicRef142975" href="/z/d/graphic/142975.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">"Pulmonic regurgitation", section on 'Intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary valve stenosis </strong>with associated criteria for intervention, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management", section on 'Indications for intervention'</a>.)</p><p></p><p class="headingAnchor" id="H2428534988"><span class="h2">Underlying conditions</span><span class="headingEndMark"> — </span>TPVI is performed in selected patients with RVOT/pulmonary valve dysfunction in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repaired native RVOT</strong> – Conditions that may be treated with RVOT repair include tetralogy of Fallot (TOF) and pulmonary atresia. (See  <a class="medical medical_review" href="/z/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RV to pulmonary artery conduit</strong> –<strong> </strong>Conditions that may be treated with an RV to pulmonary artery conduit (valved or nonvalved) include TOF, pulmonary atresia, and truncus arteriosus. (See  <a class="medical medical_review" href="/z/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair"</a> and  <a class="medical medical_review" href="/z/d/html/87462.html" rel="external">"Pulmonary atresia with intact ventricular septum (PA/IVS)"</a> and  <a class="medical medical_review" href="/z/d/html/14588.html" rel="external">"Truncus arteriosus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioprosthetic pulmonary valve dysfunction</strong> – TPVI can also be performed as a valve-in-valve procedure after failure of the primary bioprosthetic valve in the RVOT [<a href="#rid9">9</a>]. The initial bioprosthetic valve may have been placed for RVOT dysfunction or as part of a Ross procedure. The indications and the implantation techniques are the same for repeat TPVI as for primary TPVI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Native pulmonary valve stenosis or regurgitation</strong> – For patients with native pulmonary valve disease who require valve replacement, TPVI is an alternative to surgical valve replacement. (See  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management", section on 'Interventions'</a> and  <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">"Pulmonic regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">"Pulmonic regurgitation", section on 'Percutaneous'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failed pulmonary balloon valvuloplasty or surgical pulmonary valvotomy</strong> – TPVI is a potential option for selected patients with significant residual pulmonary valve stenosis or pulmonary regurgitation after balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis.</p><p></p><p class="headingAnchor" id="H2784987195"><span class="h2">Choice of procedure</span><span class="headingEndMark"> — </span>Selection of procedure for RVOT dysfunction (pulmonary regurgitation and pulmonary valve stenosis) is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Pulmonary valve replacement (PVR)'</a> and  <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">"Pulmonic regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management"</a>.)</p><p>When intervention is indicated for RVOT dysfunction, and TPVI is feasible, TPVI is commonly preferred to surgical pulmonary valve implantation to minimize procedural risk and recovery time. However, when there is a concurrent indication for a cardiac surgery (such as tricuspid annuloplasty, coronary artery bypass, or arrhythmia surgery) surgical pulmonary valve implantation is generally preferred.</p><p class="headingAnchor" id="H4196406686"><span class="h2">Exclusions</span><span class="headingEndMark"> — </span>TPVI is not performed in the following settings due to technical and/or safety concerns, as discussed in the 2020 European Society of Cardiology guidelines for the management of adult congenital heart disease endorsed by the Association for European Pediatric Cardiology [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe pulmonary valve stenosis that cannot be relieved by balloon dilation (eg, severely stenotic dysplastic valve (thickened cusps and redundant tissue as seen in Noonan syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RVOT (native or conduit) size that exceeds the limit of available devices. The RVOT size must be small enough to provide a suitable landing zone for a covered stent. There is generally no lower limit for landing zone size.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For balloon-dilatable percutaneous valves, a landing zone diameter &lt;29 mm is generally required. In selected cases, a slightly larger diameter may be successfully treated after prestenting to a smaller diameter to create a suitable "landing zone" or by overdilating an Edwards SAPIEN valve 29 to 31 mm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Self-expanding pulmonary valves enable treatment of larger RVOT anatomies. (See <a class="local">'Self-expanding valves'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate venous access from both femoral and jugular sites caused by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions such as central vein occlusion.</p><p></p><p class="bulletIndent2"><strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small body size (eg, body weight ≤20 kg). Femoral vein (or jugular vein size must be adequate for placement of the introducer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk of coronary compression by the expanded implant as determined by balloon testing  (<a class="graphic graphic_diagnosticimage graphicRef89248" href="/z/d/graphic/89248.html" rel="external">image 1</a>) [<a href="#rid10">10</a>]. (See <a class="local">'Balloon test'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active systemic infection (such as endocarditis) or high risk of systemic infection (such as intravenous drug abuse).</p><p></p><p class="headingAnchor" id="H1028520181"><span class="h1">PREPROCEDURAL EVALUATION</span><span class="headingEndMark"> — </span>A multidisciplinary assessment is performed to determine whether the patient is a candidate for pulmonary valve replacement, choice of procedure (TPVI versus surgery) and choice of valve.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Criteria for pulmonary valve replacement </strong>(for pulmonary regurgitation and/or pulmonary valve stenosis)<strong> </strong>are assessed by clinical evaluation, echocardiography, cardiovascular magnetic resonance imaging (CMR), and/or cardiac computed tomography (CT), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional role of imaging for TPVI</strong> – For patients undergoing TPVI, coronary CT angiography, CMR, and/or invasive coronary angiography may be used to assess the spatial relationship between the coronary arteries and the RVOT [<a href="#rid2">2</a>], although this is further assessed by the balloon test. (See <a class="local">'Balloon test'</a> below.)</p><p></p><p class="bulletIndent1">For self-expanding valves in native RVOTs, high-quality preinterventional three-dimensional imaging (by cardiac CT or CMR) is performed in systole and diastole. These images inform selection of a balloon size for the balloon test. (See <a class="local">'Balloon test'</a> below.)</p><p></p><p class="headingAnchor" id="H4112374155"><span class="h1">TPV DEVICES</span><span class="headingEndMark"> — </span>For patients undergoing TPVI, the choice of transcatheter pulmonary valve (TPV) is based upon availability and RV outflow tract (RVOT) size (with self-expanding valves used for the largest RVOTs, such as native RVOTs).</p><p class="headingAnchor" id="H2966380146"><span class="h2">Balloon-expandable valves</span><span class="headingEndMark"> — </span>Two balloon-expandable TPVs are US Food and Drug Administration (FDA) and CE approved. Depending on the final diameter of the treated RVOT, either a Melody valve or a SAPIEN 3 valve is chosen.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melody TPV</strong> – This valve  (<a class="graphic graphic_diagnosticimage graphicRef89249" href="/z/d/graphic/89249.html" rel="external">image 2</a>) is made from a Contegra bovine jugular vein valve hand-sewn into a 34 mm bare metal Cheatham platinum balloon-expandable intravascular stent (NuMED CP Stent CP8Z34) and is available in 2 sizes: a 16 mm valve that can be expanded up to 20 mm and an 18 mm valve that can be expanded up to 22 mm [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SAPIEN 3 TPV</strong> – The valve  (<a class="graphic graphic_diagnosticimage graphicRef89250" href="/z/d/graphic/89250.html" rel="external">image 3</a>) is made from a trileaflet bovine pericardial valve hand-sewn into a balloon-expandable stainless steel stent and is available in three sizes, 23, 26, and 29 mm, and is approved for RVOT conduit diameters from 16.5 to 29 mm (16.5 to 28.5 mm internal diameter of a failed bioprosthesis) [<a href="#rid12">12</a>]. There is a fabric-sealing cuff covering the proximal part of the stent designed to prevent paravalvular leaking.</p><p></p><p class="headingAnchor" id="H1080480283"><span class="h2">Self-expanding valves</span><span class="headingEndMark"> — </span>Two balloon expandable valves are US FDA and CE approved:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Harmony TPV</strong> – This is a self-expanding porcine pericardial valve mounted within a pericardial tube that is supported by a nitinol framework. The valve is specifically designed for use in large-diameter native outflow tracts.</p><p></p><p class="bulletIndent1">The Harmony TPV is available in two designs. It consists of a self-expanding nitinol stent with a woven polyester covering and a porcine pericardial trileaflet valve sewn into its center. The various inflow and outflow sizes are designed to accommodate a variety of native outflow tract morphologies [<a href="#rid13">13</a>]. The valve housing is 22 mm (inflow diameter 41 mm; exit diameter 32 mm; total length 55 mm) or 25 mm (inflow diameter 54 mm; exit diameter 43 mm; length 51 mm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SAPIEN 3 with Alterra adaptive prestent</strong> – This is a two-part valve system designed for valve implantation in large-diameter native RV outflow tracts. The Alterra adaptive prestent is an anchoring adaptor for the 29 mm SAPIEN 3 valve within native RVOTs.</p><p></p><p class="bulletIndent1">The prestent is made of a self-expanding, radiopaque, nitinol frame assembly covered proximally by polytetrafluoroethylene. The prestent flares symmetrically at inflow and outflow ends (40 mm diameters). The central waist of the prestent was designed to provide a stable landing zone in a dilated RVOT for a 29 mm SAPIEN 3 transcatheter valve, which is typically implanted during the same procedure [<a href="#rid14">14</a>]. The total length of the Alterra prestent is 48 mm.</p><p></p><p class="headingAnchor" id="H1294639876"><span class="h2">Other self-expanding valves</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venus P-Valve</strong> – This valve is composed of a self-expandable nitinol framework with a trileaflet porcine pericardial valve and is available in straight and flared designs in five sizes (central stent diameter 28 to 36 mm in 2 mm increments) and two lengths (central stent length 25 and 30 mm). It is loaded on a 22 or 24F delivery system. The valve is preferably implanted through a 26F 65 cm DrySeal sheath. The valve underwent several modifications since its first implantation. In 2023 it received CE mark for Europe. This valve is an investigational device in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsta TPV</strong> – This trileaflet valve consists of a double-strand nitinol wire covered with treated porcine pericardium. Valve central diameters range from 18 to 32 mm, again with 2 mm increments (thus including the smallest diameter for a self-expanding valve). Both valve end diameters flare by 4 mm greater than the central diameter. The total valve length is 28 to 38 mm. The valve is approved in South Korea and is awaiting CE certification in Europe.</p><p></p><p class="headingAnchor" id="H354444694"><span class="h1">IMPLANTATION TECHNIQUE</span><span class="headingEndMark"> — </span>TPVI is usually performed using general endotracheal anesthesia or conscious sedation. Venous access is generally obtained through the femoral vein, although a jugular venous approach is also feasible. After a complete hemodynamic and angiographic study, a guidewire is positioned distally into a pulmonary artery.</p><p class="headingAnchor" id="H10923124"><span class="h2">Balloon test</span><span class="headingEndMark"> — </span>Since coronary artery compression is a life-threatening complication of TPVI, a balloon test is performed in the RV outflow tract (RVOT) to exclude risk of this complication. This involves inflation of a balloon in the RVOT (conduit or native). The balloon test is performed prior to TPVI with any balloon expandable valve. Although coronary compression does not seem to occur often with self-expanding transcatheter pulmonary valves (TPV), a balloon test with aortogram is also frequently performed prior to TPVI with self-expanding valves.</p><p class="bulletIndent1"><span class="glyph">●</span>The balloon size is selected based upon the RVOT landing zone for the pulmonic valve. (See <a class="local">'Preprocedural evaluation'</a> above.)</p><p></p><p class="bulletIndent1">In enlarged "native" RVOTs, an RV angiogram is obtained to document total occlusion of the RVOT during balloon inflation. Based on the balloon test, an adequately sized valve is chosen, usually 2 to 4 mm larger than the waist seen in the balloon during interrogation of the landing zone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon test is initially performed with a low-pressure balloon to reduce the risk of conduit rupture. A balloon is inflated with a simultaneous aortogram to display the coronary arteries  (<a class="graphic graphic_diagnosticimage graphicRef89248" href="/z/d/graphic/89248.html" rel="external">image 1</a>) [<a href="#rid10">10</a>]. For this test, an aortogram may be preferable to a selective coronary artery angiogram because engaging the coronary artery with the catheter may lead to a false negative test.</p><p></p><p class="bulletIndent1">If the origins of the coronary arteries are in close proximity to the RVOT, a balloon test with an ultra-high-pressure balloon (ie, Atlas Kevlar) may be necessary to avoid coronary artery compression and selective coronary angiography is performed in multiple planes.</p><p></p><p class="bulletIndent1">If coronary artery flow is impaired during the balloon test, TPVI should not be performed.</p><p></p><p class="headingAnchor" id="H10923131"><span class="h2">Conduit preparation and prestenting</span><span class="headingEndMark"> — </span>If there is significant conduit stenosis, conduit balloon angioplasty and stenting is performed to reduce the RVOT gradient.</p><p>The role of prestenting varies depending upon the type of valve:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melody valve</strong> – Prestenting of the conduit before Melody valve implantation is standard practice at most centers since observational studies have found that prestenting is associated with a lower risk of TPV stent fractures [<a href="#rid15">15</a>]. Usually, a covered stent is preferred to avoid bleeding related to conduit rupture during stent deployment because high-pressure balloons are needed to dilate the conduit to the previously tested diameter. In some cases (eg, long stenosis or significant recoil during balloon deflation), additional stents are needed for prestenting to support the landing zone. A noncovered stent is usually used if obstruction of the origin of one of the pulmonary branch arteries ("jailing") is expected after deployment of the stent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SAPIEN valve</strong> – In selected patients, the SAPIEN valve may be implanted directly without prestenting since stent fracture has not been reported [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Self-expanding valves</strong> - Prestenting is not necessary for self-expanding valves (such as Harmony and Venus P-Valve) and may even be counterproductive.</p><p></p><p class="headingAnchor" id="H4192460424"><span class="h2">Valve implantation</span><span class="headingEndMark"> — </span>The implantation techniques for the Melody and SAPIEN valves are similar [<a href="#rid1">1,7,17-20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The Melody valve is crimped onto a designated double balloon delivery system requiring a 22F sheath.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SAPIEN valve is crimped onto a designated balloon delivery system requiring a 14 or 16F sheath for the 23, 26, or 29 mm valve. The SAPIEN THV is advanced without protection into the RVOT. If the THV struts get caught in the tricuspid valve, the valve may be damaged [<a href="#rid21">21</a>]. To avoid this complication, a large sheath is used for direct implantation of the valve in the RVOT [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Self-expanding valves are crimped and loaded into a delivery catheter system. The assembly is positioned over a stiff wire and then the delivery catheter is slowly withdrawn as the self-expanding valve opens. The correct valve position is depicted via a second catheter in the RVOT prior to final valve delivery.</p><p></p><p class="headingAnchor" id="H354444722"><span class="h1">COMPLICATIONS BY VALVE TYPE</span><span class="headingEndMark"> — </span>Short- and medium-term results of TPVI with the Melody and SAPIEN valves are similar, although more data are available for the Melody valve. Long-term data are available for the Melody valve, as discussed below. Long-term data are not yet available for the SAPIEN 3 valve and the self-expandable valves.</p><p class="headingAnchor" id="H4158475957"><span class="h2">For balloon-expandable valves</span><span class="headingEndMark"> — </span>Many studies show that regardless of the type of balloon-expandable valve used for TPVI, higher residual gradient correlates with unfavorable valve outcomes [<a href="#rid23">23-26</a>]. Therefore, every effort should be made to reach the lowest possible RV-pulmonary artery gradient at the end of the procedure.</p><p>An international multicenter registry study examined the results for 2476 patients who underwent TPVI with either the Melody or any Sapien valve who were followed for 8475 patient years [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A total of 95 patients died after TPVI, most commonly from heart failure (n = 24) for a cumulative incidence of death of 8.9 percent at eight years after TPVI. On multivariable analysis, age at TPVI, a prosthetic valve in other positions, and an existing transvenous pacemaker or implantable cardioverter-defibrillator were associated with death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A total of 258 patients underwent TPV reinterventions. At eight years, the cumulative incidence of any TPV reintervention was 25.1 percent and of surgical TPV reintervention was 14.4 percent. Risk factors for surgical intervention included age, prior infective endocarditis, TPVI into a stented bioprosthetic valve, and postimplant gradient.</p><p></p><p class="headingAnchor" id="H354444730"><span class="h3">Melody TPV</span><span class="headingEndMark"> — </span>Data are available from four short- and medium-term observational studies with a total of over 450 patients with one- to five-year follow-up [<a href="#rid7">7,8,27,28</a>] as well as from longer-term studies. These studies excluded 4 to 8 percent of the patients who did not undergo TPVI due to an unfavorable RV outflow tract (RVOT) dimension or coronary artery compression.</p><p>After TPVI, the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Overall operative mortality was 0 to 5 percent and was, as far as could be assessed, not related to the TPVI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The device was unstable in 1 percent, a conduit rupture requiring surgery occurred in 0.8 to 2 percent, compression of the left main coronary artery after device deployment occurred in 0 to 1 percent, and obstruction of the origin of one of the pulmonary branch arteries ("jailing") occurred in 0.6 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The RVOT gradient fell significantly from median values of 35 to 40 to 10 to 20 mmHg. Median peak velocity over the RVOT was 1.9 to 2.7 m/s at one-year echocardiographic follow-up. Pulmonary regurgitation decreased from median values of 16 to 27 percent to 1 to 2 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Freedom from Melody valve dysfunction or reintervention was 94 to 95 percent at one year. Patients not requiring reintervention had mild or less pulmonic valve regurgitation at one-year follow-up. Overall, surgery was required in 3 percent during follow-up, with freedom from reoperation of 86 percent at 30 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocarditis was diagnosed in 1 to 3 percent of the cases up to five years after TPVI with Melody valves. (See <a class="local">'Endocarditis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At six months, New York Heart Association class improved in 77 percent of the patients and worsened only in 0.8 percent. RV end-diastolic volume and RV mass decreased significantly as demonstrated by CMR imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stent fractures occurred in 20 to 21 percent in a series without prestenting and in 5 to 16 percent in a series with prestenting. (This contrasts with no reported stent fractures with the Sapien 3 valve.) (See <a class="local">'SAPIEN TPV'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an early study, the first 50 patients of the series and those with residual gradients &gt;25 mmHg had a higher risk of reoperation compared with the rest of the study group [<a href="#rid27">27</a>].</p><p></p><p>Four long-term studies on TPVI with the Melody valve have been published [<a href="#rid23">23-25,29</a>]. The best long-term results (estimated event-free survival rate of 88 percent at 10 years) were observed among patients with a RVOT residual peak invasive gradient of &lt;15 mmHg after the intervention. One study compared the long-term outcome of TPVI (Melody valve) with surgical bioprosthetic pulmonary valve replacement [<a href="#rid30">30</a>]. At 10-year follow-up, there was no difference in freedom from valve replacement between the groups.</p><p>Some data in patients with RVOT dysfunction (obstruction or regurgitation) and moderate to severe tricuspid regurgitation suggest that TPVI may cause acute reduction in the severity of tricuspid regurgitation and improvement in RV remodeling [<a href="#rid31">31,32</a>]. More data are needed on the impact of TPVI on tricuspid regurgitation.</p><p class="headingAnchor" id="H354444737"><span class="h3">SAPIEN TPV</span><span class="headingEndMark"> — </span>A multicenter study reported outcomes for SAPIEN valve implantation in 774 patients (51 percent with a native or prior RVOT patch placement; 24 percent with a conduit; and 25 percent with a bioprosthetic valve). SAPIEN valve implantation was technically successful in 97.4 percent [<a href="#rid33">33</a>]. Valve function at discharge was excellent in most patients, but 8.5 percent had moderate or greater pulmonary regurgitation or maximum Doppler gradients &gt;40 mmHg. During follow-up in 349 patients (median 12 months), nine patients were diagnosed with endocarditis, and 17 additional patients underwent surgical valve replacement or valve-in-valve TPVI.</p><p class="headingAnchor" id="H4234790257"><span class="h2">For self-expanding valves</span><span class="headingEndMark"> — </span>Follow-up data for self-expanding valves are limited to small short- to medium-term studies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Harmony TPV</strong> – A study of one-year outcomes included 87 patients who received a commercially available Harmony TPV [<a href="#rid34">34</a>]. At one year, there were no deaths and most patients had mild or less pulmonary regurgitation (98 percent of TPV22 patients, 97 percent of TPV25 patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venus-P TPV</strong> – Two multicenter follow-up studies (12 to 25 months follow-up) with a total of 93 patients showed good early results with the Venus-P TPV. Stent migration occurred in three patients, and stent frame fracture was seen in 27 percent of patients during follow-up. Most implanted valves showed excellent valve function at follow-up, and four patients had infective endocarditis [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsta TPV</strong> – A study reported successful implantation in all 25 patients receiving the Pulsta TPV for native RVOT lesions, no serious device-related adverse events, and at mean 33 months follow-up, a mean pressure gradient across the Pulsta valve of 6.5±3.0 mmHg without significant pulmonary regurgitation [<a href="#rid37">37</a>].</p><p></p><p>Initial reports of successful treatment with Harmony [<a href="#rid34">34,38</a>] and Alterra [<a href="#rid14">14</a>] are available.</p><p class="headingAnchor" id="H3148694939"><span class="h1">ACUTE COMPLICATIONS</span><span class="headingEndMark"> — </span>Acute severe complications of TPVI are uncommon. In a case series of 152 patients undergoing TPVI, six patients (4 percent) had acute complications requiring rescue surgery [<a href="#rid39">39</a>]. These included homograft rupture, dislodgement of the stented valve, occlusion of the right pulmonary artery, and compression of the left coronary artery. Data are still developing on complications for Harmony and Alterra valves.</p><p class="headingAnchor" id="H354445432"><span class="h2">Coronary artery compression</span><span class="headingEndMark"> — </span>Compression of the left main coronary artery after device deployment occurs in approximately 0 to 1 percent of all cases of TPVI and nearly always has a fatal outcome [<a href="#rid7">7,8,27,28</a>]. Therefore, a balloon test to exclude potential coronary artery compression should always be performed prior to deployment of the valve [<a href="#rid10">10</a>]. A balloon test positive for coronary artery compression was initially identified in approximately 1 percent of cases referred to TPVI [<a href="#rid27">27</a>]. A later study found coronary compression during the balloon test in 5 percent of the patients [<a href="#rid40">40</a>]. The intervention was abandoned in these cases. (See <a class="local">'Balloon test'</a> above.)</p><p>Rarely, hematoma formation from conduit laceration may cause acute extrinsic coronary artery compression requiring emergency surgery [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H354444759"><span class="h2">Conduit rupture</span><span class="headingEndMark"> — </span>Risk factors for conduit rupture include heavy calcification of the conduit and an RV outflow tract (RVOT) homograft valve [<a href="#rid42">42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Contained conduit rupture may easily be treated with covered stent implantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncontained conduit rupture is an emergency. If the rupture is not immediately controlled by covered stent implantation, emergency surgery may be necessary (less than 1 percent of patients undergoing TPVI) [<a href="#rid7">7,8,27</a>].</p><p></p><p class="headingAnchor" id="H882136580"><span class="h2">Ventricular arrhythmias</span><span class="headingEndMark"> — </span>Cardiac telemetry is routinely performed after TPVI procedures. Limited data have raised some concern about early (within the first 24 hours) postoperative ventricular tachycardia after annular implantation of self-expanding valves [<a href="#rid43">43</a>] or the Alterra adaptative stent. It has been postulated that this risk may stem from interaction between the device and native RVOT tissue.</p><p>In addition, many patients undergoing TPVI (such as those with tetralogy of Fallot) have elevated longer term risk of ventricular arrhythmias. Since Venus-P, Harmony, and Alterra are anchored in the myocardium of the RVOT, access for electrophysiologic ablation therapy may be technically challenging or even impossible after these devices have been placed. Therefore, many centers perform electrophysiologic study prior to TPVI or surgical pulmonary valve replacement, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Patients undergoing PVR'</a>.)</p><p class="headingAnchor" id="H2648544225"><span class="h1">OTHER COMPLICATIONS</span></p><p class="headingAnchor" id="H354444766"><span class="h2">Stent fracture</span><span class="headingEndMark"> — </span>The risk of transcatheter pulmonary valve (TPV) stent fracture varies among TPV valve types.</p><p class="headingAnchor" id="H3030561"><span class="h3">For Melody TPV</span><span class="headingEndMark"> — </span>Stent fractures  (<a class="graphic graphic_diagnosticimage graphicRef89251" href="/z/d/graphic/89251.html" rel="external">image 4</a>) occur in 20 to 21 percent with the Melody valve without prestenting [<a href="#rid8">8,27</a>] and in 5 to 16 percent with prestenting [<a href="#rid7">7,28</a>]. In the majority of cases, these stent fractures have no significant hemodynamic effect [<a href="#rid44">44</a>]. However, stent fractures may ultimately lead to embolization of stent parts or restenosis [<a href="#rid27">27</a>]. Risk factors for stent fracture include TPVI without prestenting (particularly with the Melody valve), severely obstructed conduits, TPVI into a native outflow tract, and presence of TPV recoil during balloon deflation [<a href="#rid44">44,45</a>].</p><p>Prestenting of the conduit with a bare metal stent before TPVI with the Melody valve is standard practice in most centers, since observational data suggest that prestenting to relieve conduit or native RV outflow tract (RVOT) obstruction may reduce the risk of stent fractures [<a href="#rid15">15,45,46</a>]. In an analysis of data from three prospective multicenter studies evaluating TPVI in patients with tetralogy of Fallot (TOF), the five-year reintervention rate among patients who had valves placed into previously stentless conduits (n = 251) was 27 percent [<a href="#rid46">46</a>]. Placement of a new prestent prior to valve implantation was associated with decreased risk of pulmonary valve prosthesis-related stent fracture (hazard ratio [HR] 0.23, 95% CI 0.10-0.55) and reintervention (HR 0.53, 95% CI 0.30-0.93).</p><p class="headingAnchor" id="H3187382864"><span class="h3">For SAPIEN 3 TPV</span><span class="headingEndMark"> — </span>Stent fractures have not been reported after TPVI with the SAPIEN 3 valve. However, in the COMPASSION study, 91 percent of the patients were prestented preceding SAPIEN implantation [<a href="#rid12">12</a>]. SAPIEN TPVI without prestenting has been performed, as illustrated by a report of 57 patients with no presenting and no stent fracture observed with median 5.7 months follow-up [<a href="#rid16">16</a>]. The rationale for this approach is that the stent of the SAPIEN valve is stronger than the stent of the Melody valve and thus may be less prone to stent fracture.</p><p class="headingAnchor" id="H532090288"><span class="h3">For self-expanding TPVs</span><span class="headingEndMark"> — </span>Limited data are available on the risk of stent fractures for self-expanding TPVs. In a series of 89 patients receiving the Harmony TPV, all patients receiving the TPV25 were free from major stent fracture at one year. One patient with implanted with the TPV22 had a major stent fracture with valve collapse at the one-month visit, treated with surgical explantation. One-year freedom from major or minor stent fracture was 90 percent in the TPV25 group and 81 percent in the TPV22 group. Thrombus was detected in one patient with a TPV25.</p><p class="headingAnchor" id="H354444773"><span class="h2">Endocarditis</span></p><p class="headingAnchor" id="H3513472200"><span class="h3">Risk</span><span class="headingEndMark"> — </span>All patients with prosthetic valves, including those who have undergone TPVI, are considered at highest risk of adverse outcomes from infective endocarditis (IE). In addition, many patients undergoing TPVI (such as those with repaired TOF) have one or more additional risk factors for endocarditis, such as the presence of residual defects at or adjacent to the site of prosthetic material and presence of a prosthetic conduit. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures", section on 'Which patients?'</a>.)</p><p>IE after TPVI has been observed in approximately 1 to 3 percent of patients during one- to four-year follow-up [<a href="#rid7">7,8,27,28,47-51</a>]. In a multicenter study of 2476 patients who underwent TPVR with a Melody or SAPIEN valve, IE was diagnosed in 7.3 percent of patients over a median follow-up of 2.7 years (incidence rate of 2.2 per 100 patient-years) [<a href="#rid48">48</a>]. Risk factors for IE included younger age, history of endocarditis prior to valve implantation, and higher residual gradient after TPVR. In this study, the type of valve (Melody or SAPIEN) was not an independent risk factor for IE.</p><p>The rate of IE after TPVI is similar to the generally observed rate of IE after surgical RVOT reconstruction, which ranges from approximately 0 to 5 percent of patients during one- to four-year follow-up [<a href="#rid52">52-59</a>]. However, the rate of IE after TPVI may be higher than that seen after RVOT reconstruction with a homograft. A retrospective study included 677 patients with 738 right ventricular outflow conduits implanted between 1989 and 2013 [<a href="#rid60">60</a>]. Kaplan-Meier survival free of IE for patients with surgically implanted homografts was 98.7 percent at five years and 97.3 percent at 10 years; for surgically implanted Contegra conduits, it was 87.8 percent at five years and 77.3 percent at 10 years; and for transcatheter Melody valves, it was 84.9 percent at five years. Thus, the Contegra conduit and Melody valved stents (both produced from bovine jugular vein) were associated with significantly higher incidence of IE than homografts. However, it should be noted that a Melody valve is often implanted in a stenotic homograft and some have postulated a possible role of undetected homograft IE. Thus, further studies are needed to clarify these important observations.</p><p>Among patients with surgical or transcatheter bioprosthetic pulmonary valves, the risk of endocarditis appears to be highest among those with bovine jugular vein valves. The mechanism is incompletely understood [<a href="#rid47">47,60</a>]. In a meta-analysis of 50 studies (most were observational) of &gt;7000 patients who underwent RV-to-pulmonary artery conduit or percutaneous pulmonary valve implantation, the overall incidence of IE was 2.6 percent; the incidence was higher in bovine jugular vein valves compared with other valves (5.4 versus 1.2 percent) [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H360635290"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Vegetations on a transcatheter pulmonic valve or conduit can be difficult to visualize by echocardiography [<a href="#rid49">49,62</a>]. A report suggested that intracardiac echocardiography can be helpful when transthoracic and transesophageal echocardiography fail to show vegetations [<a href="#rid50">50</a>]. Alternate imaging with cardiac CT, positron emission tomography, or CMR may also be helpful, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H150333682"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>Preventive measures include maintenance of oral hygiene, timely treatment of infections, and antibiotic prophylaxis for bacterial endocarditis for relevant high-risk procedures (such as all oral or dental procedures that involve manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa). Recommendations for antibiotic prophylaxis for endocarditis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p class="headingAnchor" id="H1581721448"><span class="h1">REINTERVENTION</span><span class="headingEndMark"> — </span>Reintervention within 5 to 10 years is required in approximately 20 to 25 percent of patients with tetralogy of Fallot undergoing TPVI [<a href="#rid26">26</a>]. Reasons for reintervention include stent fracture, device failure with recurrent stenosis, residual stenosis not relieved by the stent, or infection [<a href="#rid23">23,63</a>]. In one report, the most common reason for reintervention after TPVI was recurrent stenosis related to stent fracture [<a href="#rid23">23</a>]. As noted above, observational data suggest that prestenting may reduce the risk of stent fracture in patients receiving the Melody TPV. (See <a class="local">'Melody TPV'</a> above.)</p><p class="headingAnchor" id="H3213359955"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H354444780"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – Transcatheter pulmonary valve implantation (TPVI) is an alternative to surgical pulmonary valve replacement for selected patients with native or conduit right ventricular outflow tract (RVOT) dysfunction involving a bioprosthetic or native valve, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary regurgitation</strong> with associated criteria  (<a class="graphic graphic_table graphicRef142975" href="/z/d/graphic/142975.html" rel="external">table 1</a>) and mild or no nonvalvular RVOT obstruction, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary valve stenosis </strong>with associated criteria for intervention, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management", section on 'Indications for intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclusions</strong> – TPVI is not performed in the following settings due to technical and/or safety concerns: RVOT size that exceeds the limit of available devices, inadequate venous access from femoral and jugular sites, severe pulmonary valve stenosis that cannot be relieved by balloon dilation, risk of coronary compression by the expanded implant as determined by balloon testing, and active systemic infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Devices</strong> – For patients undergoing TPVI, the choice of transcatheter pulmonary valve (TPV) is based on availability and RVOT size (with self-expanding valves used for the largest RVOTs, such as native RVOTs).</p><p></p><p class="bulletIndent1">TPVs approved for use in both the United States and Europe include balloon-expandable valves (Melody and SAPIEN 3) and self-expanding valves (Harmony and SAPIEN 3 with Alterra adaptive prestent). Venus P-Valve is another self-expanding valve approved for use in Europe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balloon test</strong> – Since coronary artery compression is a life-threatening complication of TPVI, a balloon test is performed in the RVOT to exclude risk of this complication  (<a class="graphic graphic_diagnosticimage graphicRef89248" href="/z/d/graphic/89248.html" rel="external">image 1</a>). (See <a class="local">'Implantation technique'</a> above and <a class="local">'Coronary artery compression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conduit preparation and prestenting</strong> – If there is significant conduit stenosis, conduit balloon angioplasty and stenting is performed to reduce the RVOT gradient. Prestenting of the conduit before Melody valve implantation is standard practice at most centers, since prestenting is associated with lower risk of TPV stent fractures. Prestenting is not required prior to SAPIEN valve or self-expanding valve implantation. (See <a class="local">'Conduit preparation and prestenting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The most common complication following TPVI with the Melody valve without prestenting is stent fracture, which usually is hemodynamically benign. Uncommon complications occurring in 2 percent or less of patients include clinically significant conduit rupture, coronary artery compression, ventricular arrhythmias, and endocarditis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocarditis</strong> – Patients who have undergone TPVI are considered among those at highest risk for adverse outcomes from infective endocarditis (IE). Preventive measures include antibiotic prophylaxis for invasive dental or oral procedures. (See <a class="local">'Endocarditis'</a> above and  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 2000; 356:1403.</a></li><li><a class="nounderline abstract_t">Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42:563.</a></li><li><a class="nounderline abstract_t">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e698.</a></li><li><a class="nounderline abstract_t">Boudjemline Y, Brugada G, Van-Aerschot I, et al. Outcomes and safety of transcatheter pulmonary valve replacement in patients with large patched right ventricular outflow tracts. Arch Cardiovasc Dis 2012; 105:404.</a></li><li><a class="nounderline abstract_t">Gillespie MJ, Rome JJ, Levi DS, et al. Melody valve implant within failed bioprosthetic valves in the pulmonary position: a multicenter experience. Circ Cardiovasc Interv 2012; 5:862.</a></li><li><a class="nounderline abstract_t">Eicken A, Hess J. Percutaneous pulmonary valve implantation: the Munich experience. Interventional Cardiology 2012; 4:193.</a></li><li><a class="nounderline abstract_t">Eicken A, Ewert P, Hager A, et al. Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients. Eur Heart J 2011; 32:1260.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. Circulation 2010; 122:507.</a></li><li><a class="nounderline abstract_t">Nordmeyer J, Coats L, Lurz P, et al. Percutaneous pulmonary valve-in-valve implantation: a successful treatment concept for early device failure. Eur Heart J 2008; 29:810.</a></li><li><a class="nounderline abstract_t">Sridharan S, Coats L, Khambadkone S, et al. Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: the risk to the coronary circulation. Circulation 2006; 113:e934.</a></li><li class="breakAll">FDA Approval letter. Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Valve Delivery System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140017a.pdf (Accessed on January 27, 2015).</li><li><a class="nounderline abstract_t">Kenny D, Rhodes JF, Fleming GA, et al. 3-Year Outcomes of the Edwards SAPIEN Transcatheter Heart Valve for Conduit Failure in the Pulmonary Position From the COMPASSION Multicenter Clinical Trial. JACC Cardiovasc Interv 2018; 11:1920.</a></li><li><a class="nounderline abstract_t">Benson LN, Gillespie MJ, Bergersen L, et al. Three-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study. Circ Cardiovasc Interv 2020; 13:e008320.</a></li><li><a class="nounderline abstract_t">Shahanavaz S, Balzer D, Babaliaros V, et al. Alterra Adaptive Prestent and SAPIEN 3 THV for Congenital Pulmonic Valve Dysfunction: An Early Feasibility Study. JACC Cardiovasc Interv 2020; 13:2510.</a></li><li><a class="nounderline abstract_t">Nordmeyer J, Lurz P, Khambadkone S, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes. Heart 2011; 97:118.</a></li><li><a class="nounderline abstract_t">Morgan GJ, Sadeghi S, Salem MM, et al. SAPIEN valve for percutaneous transcatheter pulmonary valve replacement without "pre-stenting": A multi-institutional experience. Catheter Cardiovasc Interv 2019; 93:324.</a></li><li><a class="nounderline abstract_t">Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. J Am Coll Cardiol 2009; 54:1722.</a></li><li><a class="nounderline abstract_t">Garay F, Webb J, Hijazi ZM. Percutaneous replacement of pulmonary valve using the Edwards-Cribier percutaneous heart valve: first report in a human patient. Catheter Cardiovasc Interv 2006; 67:659.</a></li><li><a class="nounderline abstract_t">Boone RH, Webb JG, Horlick E, et al. Transcatheter pulmonary valve implantation using the Edwards SAPIEN transcatheter heart valve. Catheter Cardiovasc Interv 2010; 75:286.</a></li><li><a class="nounderline abstract_t">Kenny D, Hijazi ZM, Kar S, et al. Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol 2011; 58:2248.</a></li><li><a class="nounderline abstract_t">Faccini A, Butera G. Tricuspid regurgitation as a complication of Edwards Sapien XT valve implantation in pulmonary position a problem to deal with. Catheter Cardiovasc Interv 2018; 91:927.</a></li><li><a class="nounderline abstract_t">Kenny D, Morgan GJ, Murphy M, et al. Use of 65 cm large caliber Dryseal sheaths to facilitate delivery of the Edwards SAPIEN valve to dysfunctional right ventricular outflow tracts. Catheter Cardiovasc Interv 2019; 94:409.</a></li><li><a class="nounderline abstract_t">Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation 2015; 131:1960.</a></li><li><a class="nounderline abstract_t">Nordmeyer J, Ewert P, Gewillig M, et al. Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation. Eur Heart J 2019; 40:2255.</a></li><li><a class="nounderline abstract_t">Georgiev S, Ewert P, Tanase D, et al. A Low Residual Pressure Gradient Yields Excellent Long-Term Outcome After Percutaneous Pulmonary Valve Implantation. JACC Cardiovasc Interv 2019; 12:1594.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and Survival After Transcatheter Pulmonary Valve Replacement. J Am Coll Cardiol 2022; 79:18.</a></li><li><a class="nounderline abstract_t">Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation 2008; 117:1964.</a></li><li><a class="nounderline abstract_t">Butera G, Milanesi O, Spadoni I, et al. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian Society of Pediatric Cardiology. Catheter Cardiovasc Interv 2013; 81:310.</a></li><li><a class="nounderline abstract_t">Cools B, Brown S, Budts W, et al. Up to 11 years of experience with the Melody valved stent in the right ventricular outflow tract. EuroIntervention 2018; 14:e988.</a></li><li><a class="nounderline abstract_t">Georgiev S, Ewert P, Eicken A, et al. Munich Comparative Study: Prospective Long-Term Outcome of the Transcatheter Melody Valve Versus Surgical Pulmonary Bioprosthesis With Up to 12 Years of Follow-Up. Circ Cardiovasc Interv 2020; 13:e008963.</a></li><li><a class="nounderline abstract_t">Jones TK, Rome JJ, Armstrong AK, et al. Transcatheter Pulmonary Valve Replacement Reduces Tricuspid Regurgitation in Patients With Right Ventricular Volume/Pressure Overload. J Am Coll Cardiol 2016; 68:1525.</a></li><li><a class="nounderline abstract_t">Tanase D, Ewert P, Georgiev S, et al. Tricuspid Regurgitation Does Not Impact Right Ventricular Remodeling After Percutaneous Pulmonary Valve Implantation. JACC Cardiovasc Interv 2017; 10:701.</a></li><li><a class="nounderline abstract_t">Shahanavaz S, Zahn EM, Levi DS, et al. Transcatheter Pulmonary Valve Replacement With the Sapien Prosthesis. J Am Coll Cardiol 2020; 76:2847.</a></li><li><a class="nounderline abstract_t">Gillespie MJ, McElhinney DB, Jones TK, et al. 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. JACC Cardiovasc Interv 2023; 16:1917.</a></li><li><a class="nounderline abstract_t">Morgan G, Prachasilchai P, Promphan W, et al. Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve: international experience. EuroIntervention 2019; 14:1363.</a></li><li><a class="nounderline abstract_t">Zhou D, Pan W, Jilaihawi H, et al. A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results. EuroIntervention 2019; 14:1371.</a></li><li><a class="nounderline abstract_t">Lee SY, Kim GB, Kim SH, et al. Mid-term outcomes of the Pulsta transcatheter pulmonary valve for the native right ventricular outflow tract. Catheter Cardiovasc Interv 2021; 98:E724.</a></li><li><a class="nounderline abstract_t">Gillespie MJ, Bergersen L, Benson LN, et al. 5-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study. JACC Cardiovasc Interv 2021; 14:816.</a></li><li><a class="nounderline abstract_t">Kostolny M, Tsang V, Nordmeyer J, et al. Rescue surgery following percutaneous pulmonary valve implantation. Eur J Cardiothorac Surg 2008; 33:607.</a></li><li><a class="nounderline abstract_t">Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience. Circ Cardiovasc Interv 2013; 6:535.</a></li><li><a class="nounderline abstract_t">Mauri L, Frigiola A, Butera G. Emergency surgery for extrinsic coronary compression after percutaneous pulmonary valve implantation. Cardiol Young 2013; 23:463.</a></li><li><a class="nounderline abstract_t">Boudjemline Y, Malekzadeh-Milani S, Patel M, et al. Predictors and outcomes of right ventricular outflow tract conduit rupture during percutaneous pulmonary valve implantation: a multicentre study. EuroIntervention 2016; 11:1053.</a></li><li><a class="nounderline abstract_t">Taylor A, Yang J, Dubin A, et al. Ventricular arrhythmias following transcatheter pulmonary valve replacement with the harmony TPV25 device. Catheter Cardiovasc Interv 2022; 100:766.</a></li><li><a class="nounderline abstract_t">Nordmeyer J, Khambadkone S, Coats L, et al. Risk stratification, systematic classification, and anticipatory management strategies for stent fracture after percutaneous pulmonary valve implantation. Circulation 2007; 115:1392.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv 2011; 4:602.</a></li><li><a class="nounderline abstract_t">Cabalka AK, Hellenbrand WE, Eicken A, et al. Relationships Among Conduit Type, Pre-Stenting, and Outcomes in Patients Undergoing Transcatheter Pulmonary Valve Replacement in the Prospective North American and European Melody Valve Trials. JACC Cardiovasc Interv 2017; 10:1746.</a></li><li><a class="nounderline abstract_t">Buber J, Bergersen L, Lock JE, et al. Bloodstream infections occurring in patients with percutaneously implanted bioprosthetic pulmonary valve: a single-center experience. Circ Cardiovasc Interv 2013; 6:301.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Zhang Y, Aboulhosn JA, et al. Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement. J Am Coll Cardiol 2021; 78:575.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Benson LN, Eicken A, et al. Infective endocarditis after transcatheter pulmonary valve replacement using the Melody valve: combined results of 3 prospective North American and European studies. Circ Cardiovasc Interv 2013; 6:292.</a></li><li><a class="nounderline abstract_t">Cheung G, Vejlstrup N, Ihlemann N, et al. Infective endocarditis following percutaneous pulmonary valve replacement: diagnostic challenges and application of intra-cardiac echocardiography. Int J Cardiol 2013; 169:425.</a></li><li><a class="nounderline abstract_t">Dilber D, Hörer J, Malcic I, et al. Percutaneous pulmonary valve implantation and surgical valve replacement in patients with right ventricular outflow tract dysfunction--a complementary treatment concept. Int J Cardiol 2013; 169:e3.</a></li><li><a class="nounderline abstract_t">Corno AF, Hurni M, Griffin H, et al. Bovine jugular vein as right ventricle-to-pulmonary artery valved conduit. J Heart Valve Dis 2002; 11:242.</a></li><li><a class="nounderline abstract_t">Breymann T, Boethig D, Goerg R, Thies WR. The Contegra bovine valved jugular vein conduit for pediatric RVOT reconstruction: 4 years experience with 108 patients. J Card Surg 2004; 19:426.</a></li><li><a class="nounderline abstract_t">Bové T, Demanet H, Wauthy P, et al. Early results of valved bovine jugular vein conduit versus bicuspid homograft for right ventricular outflow tract reconstruction. Ann Thorac Surg 2002; 74:536.</a></li><li><a class="nounderline abstract_t">Carrel T, Berdat P, Pavlovic M, Pfammatter JP. The bovine jugular vein: a totally integrated valved conduit to repair the right ventricular outflow. J Heart Valve Dis 2002; 11:552.</a></li><li><a class="nounderline abstract_t">Boudjemline Y, Bonnet D, Massih TA, et al. Use of bovine jugular vein to reconstruct the right ventricular outflow tract: early results. J Thorac Cardiovasc Surg 2003; 126:490.</a></li><li><a class="nounderline abstract_t">Tiete AR, Sachweh JS, Roemer U, et al. Right ventricular outflow tract reconstruction with the Contegra bovine jugular vein conduit: a word of caution. Ann Thorac Surg 2004; 77:2151.</a></li><li><a class="nounderline abstract_t">Meyns B, Van Garsse L, Boshoff D, et al. The Contegra conduit in the right ventricular outflow tract induces supravalvular stenosis. J Thorac Cardiovasc Surg 2004; 128:834.</a></li><li><a class="nounderline abstract_t">Shebani SO, McGuirk S, Baghai M, et al. Right ventricular outflow tract reconstruction using Contegra valved conduit: natural history and conduit performance under pressure. Eur J Cardiothorac Surg 2006; 29:397.</a></li><li><a class="nounderline abstract_t">Van Dijck I, Budts W, Cools B, et al. Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants. Heart 2015; 101:788.</a></li><li><a class="nounderline abstract_t">Sharma A, Cote AT, Hosking MCK, Harris KC. A Systematic Review of Infective Endocarditis in Patients With Bovine Jugular Vein Valves Compared With Other Valve Types. JACC Cardiovasc Interv 2017; 10:1449.</a></li><li><a class="nounderline abstract_t">Miranda WR, Connolly HM, Bonnichsen CR, et al. Prosthetic pulmonary valve and pulmonary conduit endocarditis: clinical, microbiological and echocardiographic features in adults. Eur Heart J Cardiovasc Imaging 2016; 17:936.</a></li><li><a class="nounderline abstract_t">Schievano S, Petrini L, Migliavacca F, et al. Finite element analysis of stent deployment: understanding stent fracture in percutaneous pulmonary valve implantation. J Interv Cardiol 2007; 20:546.</a></li></ol></div><div id="topicVersionRevision">Topic 86481 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052583" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860028" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2020 ESC Guidelines for the management of adult congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22958883" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Outcomes and safety of transcatheter pulmonary valve replacement in patients with large patched right ventricular outflow tracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212395" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Melody valve implant within failed bioprosthetic valves in the pulmonary position: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Percutaneous pulmonary valve implantation: the Munich experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273201" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644013" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316357" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Percutaneous pulmonary valve-in-valve implantation: a successful treatment concept for early device failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801469" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: the risk to the coronary circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801469" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: the risk to the coronary circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30286853" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 3-Year Outcomes of the Edwards SAPIEN Transcatheter Heart Valve for Conduit Failure in the Pulmonary Position From the COMPASSION Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32525412" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Three-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33069657" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Alterra Adaptive Prestent and SAPIEN 3 THV for Congenital Pulmonic Valve Dysfunction: An Early Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965979" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30351525" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : SAPIEN valve for percutaneous transcatheter pulmonary valve replacement without "pre-stenting": A multi-institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850214" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586515" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Percutaneous replacement of pulmonary valve using the Edwards-Cribier percutaneous heart valve: first report in a human patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924775" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transcatheter pulmonary valve implantation using the Edwards SAPIEN transcatheter heart valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22078433" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405557" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tricuspid regurgitation as a complication of Edwards Sapien XT valve implantation in pulmonary position a problem to deal with.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31408262" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use of 65 cm large caliber Dryseal sheaths to facilitate delivery of the Edwards SAPIEN valve to dysfunctional right ventricular outflow tracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944758" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005985" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31202951" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A Low Residual Pressure Gradient Yields Excellent Long-Term Outcome After Percutaneous Pulmonary Valve Implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34991785" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reintervention and Survival After Transcatheter Pulmonary Valve Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391109" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718682" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian Society of Pediatric Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957592" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Up to 11 years of experience with the Melody valved stent in the right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32600110" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Munich Comparative Study: Prospective Long-Term Outcome of the Transcatheter Melody Valve Versus Surgical Pulmonary Bioprosthesis With Up to 12 Years of Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27687194" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Transcatheter Pulmonary Valve Replacement Reduces Tricuspid Regurgitation in Patients With Right Ventricular Volume/Pressure Overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385408" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tricuspid Regurgitation Does Not Impact Right Ventricular Remodeling After Percutaneous Pulmonary Valve Implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33303074" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Transcatheter Pulmonary Valve Replacement With the Sapien Prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37278682" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30248020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve: international experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398963" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34227733" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mid-term outcomes of the Pulsta transcatheter pulmonary valve for the native right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33826508" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 5-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18255307" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rescue surgery following percutaneous pulmonary valve implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065444" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23176808" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Emergency surgery for extrinsic coronary compression after percutaneous pulmonary valve implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25244126" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Predictors and outcomes of right ventricular outflow tract conduit rupture during percutaneous pulmonary valve implantation: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198126" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ventricular arrhythmias following transcatheter pulmonary valve replacement with the harmony TPV25 device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339542" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk stratification, systematic classification, and anticipatory management strategies for stent fracture after percutaneous pulmonary valve implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22075927" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28823778" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Relationships Among Conduit Type, Pre-Stenting, and Outcomes in Patients Undergoing Transcatheter Pulmonary Valve Replacement in the Prospective North American and European Melody Valve Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23756696" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bloodstream infections occurring in patients with percutaneously implanted bioprosthetic pulmonary valve: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34353535" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735475" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infective endocarditis after transcatheter pulmonary valve replacement using the Melody valve: combined results of 3 prospective North American and European studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182680" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Infective endocarditis following percutaneous pulmonary valve replacement: diagnostic challenges and application of intra-cardiac echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074726" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Percutaneous pulmonary valve implantation and surgical valve replacement in patients with right ventricular outflow tract dysfunction--a complementary treatment concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000167" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bovine jugular vein as right ventricle-to-pulmonary artery valved conduit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383054" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Contegra bovine valved jugular vein conduit for pediatric RVOT reconstruction: 4 years experience with 108 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173841" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Early results of valved bovine jugular vein conduit versus bicuspid homograft for right ventricular outflow tract reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12150305" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The bovine jugular vein: a totally integrated valved conduit to repair the right ventricular outflow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928649" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of bovine jugular vein to reconstruct the right ventricular outflow tract: early results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172286" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Right ventricular outflow tract reconstruction with the Contegra bovine jugular vein conduit: a word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15573067" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Contegra conduit in the right ventricular outflow tract induces supravalvular stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439155" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Right ventricular outflow tract reconstruction using Contegra valved conduit: natural history and conduit performance under pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25539944" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728659" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Systematic Review of Infective Endocarditis in Patients With Bovine Jugular Vein Valves Compared With Other Valve Types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161836" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prosthetic pulmonary valve and pulmonary conduit endocarditis: clinical, microbiological and echocardiographic features in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042059" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Finite element analysis of stent deployment: understanding stent fracture in percutaneous pulmonary valve implantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
